Research
Hormonal
A single session of HIIT reduces same-day postprandial glucose excursions in individuals with impaired fasting glucose or type 2 diabetes, offering acute metabolic benefits.
Doing one session of HIIT can help lower your blood sugar spikes after meals, even if you have type 2 diabetes or impaired fasting glucose. This acute benefit occurs on the same day as the exercise, suggesting that regular HIIT sessions can help manage daily glucose fluctuations.
ModerateSupportsMEDIUM confidence
Relative to no exercise, a single session of HIIT reduces same-day postprandial area under the glucose curve in those with impaired fasting glucose [22] or type 2 diabetes [23, 24].
Why this rating
Based on multiple studies cited in the review, though consistency on 24-hour mean glucose is less clear.
Source
High-intensity interval training: a review of its impact on glucose control and cardiometabolic health
Sophie Cassidy et al. · Diabetologia · 2016
DOI 10.1007/s00125-016-4106-1
narrative_reviewCited 231×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High-intensity interval training (HIIT) induces skeletal muscle molecular adaptations, including increased GLUT-4 content and mitochondrial biogenesis, which improve glucose disposal and insulin sensitivity in patients with metabolic diseases.Moderate
- HIIT improves cardiovascular function in patients with metabolic diseases by increasing end-diastolic volume, stroke volume, and flow-mediated dilation, and reducing arterial stiffness.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →